Bodyport
Bodyport is a San Francisco digital health company that has developed the FDA-cleared Cardiac Scale and Congestion Index algorithm to non-invasively detect worsening heart failure in patients at home, serving U.S. health systems and heart failure patients through remote patient monitoring.
- Company typePrivate
- Founded2015
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bodyport does
Bodyport is a San Francisco-based, venture-backed digital health company founded in 2015 that has built an FDA-cleared Fluid Management Platform centered on the Bodyport Cardiac Scale and the Congestion Index algorithm. The Cardiac Scale is a non-invasive device that captures hemodynamic biomarkers through a patient's feet in under 30 seconds during a normal daily weighing step, transmitting data over a cellular connection to care teams — eliminating the need for Bluetooth pairing, Wi-Fi, smartphones, or surgical implants. The Congestion Index combines multiple hemodynamic biomarkers into a composite metric that, in the SCALE-HF 1 clinical study (329 enrolled participants across 8 sites, 238 patient-years of follow-up, published in the Journal of Cardiac Failure), detected 70% of heart failure events versus 35% for conventional weight-based monitoring, with 14 days of average lead time and 38% fewer false alerts.
The platform is delivered through three integrated surfaces: a Care Portal clinical dashboard for triage and intervention, a Patient Portal app for self-management, and a robust API for EHR integration. The system is HIPAA-compliant and SOC 2 Type 2 certified, and includes built-in support for Remote Patient Monitoring (RPM) billing codes to streamline provider reimbursement. Bodyport generates revenue through hardware sales of the Cardiac Scale and subscription-based RPM services sold via enterprise field sales to health systems and healthcare providers.
Bodyport serves U.S. health systems and providers managing heart failure and cardiorenal patient populations, with clinical research and deployment partnerships involving Geisinger, Stanford, Duke, Yale, Brigham and Women's Hospital, the Duke Clinical Research Institute, Keck Medical Center of USC, and Boehringer Ingelheim. The company has raised approximately $15.8 million in total disclosed venture funding across rounds led by investors including Playground Global, Initialized Capital, Boehringer Ingelheim Venture Fund, Rock Health, Kapor Capital, and Y Combinator. Leadership includes CEO John Lipman (appointed June 2022), co-founder Corey Centen as President and CTO, CCO Amit Rushi, and a board chaired by Phyllis Whiteley, Ph.D. (Playground Global).
Bodyport firmographics
Firmographics- Name
- Bodyport
- Legal name
- Bodyport Inc.
- Website
- https://bodyport.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Bodyport is a San Francisco digital health company that has developed the FDA-cleared Cardiac Scale and Congestion Index algorithm to non-invasively detect worsening heart failure in patients at home, serving U.S. health systems and heart failure patients through remote patient monitoring.
- Ownership category
- akta.pro rank
Bodyport industry classification
Industry- Product category
- Remote Cardiac Monitoring
- akta.pro primary industry
- Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)
- akta.pro secondary industries
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Chronic Care & Remote Patient Monitoring (RPM) Platforms (HLALABAF)
Keywords
Where Bodyport is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Bodyport business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Remote Patient Monitoring (RPM) Billing: Platform supports RPM billing codes enabling healthcare providers to bill for remote monitoring services. The company generates revenue through health system partnerships and reimbursement for remote monitoring services.
- Hardware Device Sales: Sale of Bodyport Cardiac Scale devices to health systems and healthcare providers for patient use.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Bodyport product offering
Product offeringCore offering
Bodyport develops and sells the FDA 510(k)-cleared Bodyport Cardiac Scale, a non-invasive connected scale that captures hemodynamic biomarkers through a patient's feet in under 30 seconds and transmits the data via cellular connection. It combines the hardware with the Congestion Index algorithm and a connected software platform (Care Portal for clinicians and Patient Portal for patients) to detect early signs of worsening heart failure and enable proactive in-home care.
Product overview
Bodyport is a biomarker-guided digital therapeutics company offering a Fluid Management Platform centered on the FDA-cleared Bodyport Cardiac Scale hardware and the Congestion Index algorithm. The platform includes the Care Portal (Clinical Dashboard) for healthcare providers and a Patient Portal for at-home monitoring. Patients step barefoot on the Cardiac Scale for ~30 seconds daily, with hemodynamic data automatically transmitted via cellular to care teams. The Congestion Index algorithm analyzes multiple biomarkers to detect worsening heart failure with 70% sensitivity (vs 35% for weight-based monitoring).
Differentiator
Problem solved
Functional benefit
Brands
- Bodyport Cardiac Scale: FDA-cleared scale device that non-invasively measures hemodynamic biomarkers through a patient's feet to assess heart function and fluid status.
- Congestion Index
- Bodyport Care Portal
- Bodyport Patient App
Products and services
- Bodyport Cardiac Scale FDA-cleared, non-invasive connected scale that measures hemodynamic biomarkers through a patient's feet in under 30 seconds using advanced sensors and proprietary algorithms, and transmits the data over a cellular connection to care teams for at-home heart failure and fluid status monitoring. Sold to health systems and healthcare providers for patient use.
- Congestion Index Advanced composite algorithm that combines multiple hemodynamic biomarkers captured by the Bodyport Cardiac Scale into a single metric for early detection of worsening heart failure; demonstrated 70% heart failure event detection vs 35% for weight-based monitoring in the SCALE-HF 1 study. Delivered to health systems as part of the Bodyport platform.
- Bodyport Care Portal (Clinical Dashboard)
Quantifiable outcome
- Detects 70% of heart failure events vs 35% for weight-based monitoring
- +3 more outcomes
Companies that use Bodyport
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Bodyport technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Bodyport partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- GeisingercoreLeading health system partner collaborating with Bodyport on heart failure care solutions. Part of visible logo display on website indicating active partnership.
- StanfordcoreAcademic medical center partner in research and clinical validation of Bodyport technology.
- Duke Clinical Research Institute (DCRI)coreLeading clinical research organization partnering on SCALE-HF studies and heart failure research.
- YalecoreAcademic partner in research and clinical validation of Bodyport technology.
- Brigham and Women's HospitalcoreLeading academic medical center partner in research and clinical studies.
- Duke UniversitycoreAcademic partner with Dr. Adam DeVore serving as SCALE-HF principal investigator.
- Boehringer IngelheimcorePharmaceutical partner collaborating on cardiorenal conditions research and solutions.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Bodyport competitors and assessment
Company assessmentDirect peers
- Abbott: Markets the CardioMEMS HF System, the leading FDA-approved implantable hemodynamic monitor for heart failure. CardioMEMS directly competes with Bodyport's cardiac scale by providing continuous PA pressure data to clinicians, though it requires an implantable sensor while Bodyport is non-invasive.
- Vectorious Medical Technologies: Develops a miniaturized, implantable left-atrial pressure sensor for heart failure patients. Direct competitor in next-generation hemodynamic monitoring for HF; competing modality (implantable vs. Bodyport's non-invasive scale) but same target use case and clinical claim.
- Eko Health: Combines digital stethoscopes with AI algorithms for cardiac and pulmonary disease detection. Comparable as a hardware-plus-AI cardiac diagnostics company targeting clinicians, with FDA-cleared AI algorithms for heart murmur and AFib detection.
- iRhythm Technologies: Provider of ambulatory cardiac monitoring (Zio long-term continuous ECG patch) with AI-based arrhythmia detection. Direct peer in connected cardiac monitoring services with established reimbursement and IDN relationships, though focused on arrhythmias rather than HF congestion.
- AliveCor: Maker of KardiaMobile personal ECG devices with AI-based cardiac monitoring. Comparable as a connected, AI-driven cardiac monitoring company with both consumer and clinical channels targeting chronic cardiac condition management.
Broad incumbents
- Edwards Lifesciences: A leading cardiovascular device company with hemodynamic monitoring expertise (Swan-Ganz catheters, FloTrac, Acumen IQ). Comparable as a broader incumbent in cardiac diagnostics and monitoring, though Edwards primarily operates in acute and surgical care settings rather than at-home RPM.
- HeartFlow: AI-driven non-invasive cardiac diagnostics (FFR-CT) for coronary artery disease. Broader incumbent in non-invasive, imaging- and AI-based cardiac diagnostics used by cardiologists and health systems for decision support.
- Withings: Connected consumer health devices including smart scales, blood pressure monitors, and sleep mats. Adjacent competitor in the connected home-health device category, though Withings targets general wellness rather than clinical HF management.
Emerging players
- Sensydia: Develops non-invasive, AI-enabled cardiac function assessment platforms. Closely comparable to Bodyport in using non-invasive sensors plus proprietary algorithms to evaluate cardiac performance, though Sensydia targets pulmonary and cardiac acoustic biomarkers.
- Cleerly: AI-driven coronary CT angiography analysis for plaque and ischemia assessment. Comparable as an emerging AI-native cardiac diagnostics company with strong health-system commercial traction and category-defining clinical evidence.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Bodyport social profiles
Digital presenceBodyport compliance and trust
Trust signalCompliance2 records
Bodyport financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bodyport leadership team
Management profileNumber of profiles
Profiles9 records
Bodyport funding detail
Funding detailFunding overview
Funding rounds5 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bodyport M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bodyport
What does Bodyport do?
Bodyport develops and sells the FDA 510(k)-cleared Bodyport Cardiac Scale, a non-invasive connected scale that captures hemodynamic biomarkers through a patient's feet in under 30 seconds and transmits the data via cellular connection. It combines the hardware with the Congestion Index algorithm and a connected software platform (Care Portal for clinicians and Patient Portal for patients) to detect early signs of worsening heart failure and enable proactive in-home care.
Is Bodyport a public or private company?
Bodyport is a private company. It is classified as venture growth investor backed and is currently operating.
When was Bodyport founded?
Bodyport was founded in 2015. It employs 11 to 50 people.
Where is Bodyport based?
Bodyport is headquartered in San Francisco, United States, in the North America region.
How does Bodyport make money?
Two revenue lines are on record. Remote Patient Monitoring (RPM) Billing is the primary driver. The others are hardware Device Sales.
Who are Bodyport's main competitors?
Direct peers on record are Abbott, Vectorious Medical Technologies, Eko Health, iRhythm Technologies and AliveCor. Broad incumbents are Edwards Lifesciences, HeartFlow and Withings. Emerging players are Sensydia and Cleerly.
Does Bodyport have an API?
Yes. A robust API enables seamless integration with leading EHRs and third-party systems. The API supports RPM billing and enables clinical data transmission from the Bodyport Cardiac Scale to care teams.
What industry is Bodyport in?
Bodyport's product category is Remote Cardiac Monitoring. Its primary akta.pro industry code is HLACAPAI, Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity).